CSPC Pharmaceutical Group First Quarter 2024 Earnings: Beats Expectations

CSPC Pharmaceutical Group (HKG:1093) First Quarter 2024 Results

Key Financial Results

• Revenue: CN¥8.98b (up 12% from 1Q 2023).
• Net income: CN¥1.61b (up 13% from 1Q 2023).
• Profit margin: 18% (in line with 1Q 2023).
• EPS: CN¥0.14 (up from CN¥0.12 in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

CSPC Pharmaceutical Group Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 7.0% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for CSPC Pharmaceutical Group that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.